These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16307208)

  • 1. Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients.
    Waterhouse TH; Redmann S; Duffull SB; Eccleston JA
    J Pharmacokinet Pharmacodyn; 2005 Aug; 32(3-4):521-45. PubMed ID: 16307208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients.
    Hennig S; Waterhouse TH; Bell SC; France M; Wainwright CE; Miller H; Charles BG; Duffull SB
    Br J Clin Pharmacol; 2007 Apr; 63(4):438-50. PubMed ID: 17073891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients.
    Hennig S; Wainwright CE; Bell SC; Miller H; Friberg LE; Charles BG
    Clin Pharmacokinet; 2006; 45(11):1099-114. PubMed ID: 17048974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhalable highly concentrated itraconazole nanosuspension for the treatment of bronchopulmonary aspergillosis.
    Rundfeldt C; Steckel H; Scherliess H; Wyska E; Wlaź P
    Eur J Pharm Biopharm; 2013 Jan; 83(1):44-53. PubMed ID: 23064325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Itraconazole and allergic bronchopulmonary aspergillosis in twin brothers with cystic fibrosis.
    Mannes GP; van der Heide S; van Aalderen WM; Gerritsen J
    Lancet; 1993 Feb; 341(8843):492. PubMed ID: 8094509
    [No Abstract]   [Full Text] [Related]  

  • 6. Sputum itraconazole concentrations in cystic fibrosis patients.
    Sermet-Gaudelus I; Lesne-Hulin A; Lenoir G; Singlas E; Berche P; Hennequin C
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1937-8. PubMed ID: 11353659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allergic bronchopulmonary aspergillosis in two patients with cystic fibrosis.
    Anadol D; Ozçelik U; Kiper N; Göçmen A
    Turk J Pediatr; 2000; 42(1):68-71. PubMed ID: 10731875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Relative Bioavailability of Orally Administered Innovator-Formulated Itraconazole Capsules and Solution in Healthy Dogs.
    Hasbach AE; Langlois DK; Rosser EJ; Papich MG
    J Vet Intern Med; 2017 Jul; 31(4):1163-1169. PubMed ID: 28627123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers.
    Barone JA; Moskovitz BL; Guarnieri J; Hassell AE; Colaizzi JL; Bierman RH; Jessen L
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1862-5. PubMed ID: 9661037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspergillosis.
    Hiller EJ
    J R Soc Med; 1992; 85 Suppl 19(Suppl 19):33-5. PubMed ID: 1317918
    [No Abstract]   [Full Text] [Related]  

  • 11. Itraconazole oral solution: pharmacokinetics and absorption.
    Saag M
    AIDS Patient Care STDS; 1997 Feb; 11 Suppl 1():S16-7. PubMed ID: 11361746
    [No Abstract]   [Full Text] [Related]  

  • 12. [Respiratory deterioration and allergic bronchopulmonary aspergillosis in cystic fibrosis].
    Salcedo Posadas A
    Enferm Infecc Microbiol Clin; 2000; 18(6):301-3. PubMed ID: 11075497
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis.
    Conway SP; Etherington C; Peckham DG; Brownlee KG; Whitehead A; Cunliffe H
    J Antimicrob Chemother; 2004 May; 53(5):841-7. PubMed ID: 15044430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voriconazole pharmacokinetics and photosensitivity in children with cystic fibrosis.
    Markantonis SL; Katelari A; Pappa E; Doudounakis S
    J Cyst Fibros; 2012 May; 11(3):246-52. PubMed ID: 22284963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cystic fibrosis: current therapy. Allergic bronchopulmonary aspergillosis (ABPA)].
    Aebischer CC; Schöni MH
    Schweiz Med Wochenschr Suppl; 2000; 122():53S-54S. PubMed ID: 12536477
    [No Abstract]   [Full Text] [Related]  

  • 16. Pulse intravenous methylprednisolone for resistant allergic bronchopulmonary aspergillosis in cystic fibrosis.
    Thomson JM; Wesley A; Byrnes CA; Nixon GM
    Pediatr Pulmonol; 2006 Feb; 41(2):164-70. PubMed ID: 16317722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of itraconazole solution after a single oral administration in captive lesser flamingos (Phoeniconaias minor).
    Sánchez CR; Zalesak S; Pich AA; Papich MG
    J Vet Pharmacol Ther; 2019 Jan; 42(1):1-6. PubMed ID: 30302773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rapid HPLC method with fluorometric detection for determination of plasma itraconazole and hydroxy-itraconazole concentrations in cystic fibrosis children with allergic bronchopulmonary aspergillosis.
    Redmann S; Charles BG
    Biomed Chromatogr; 2006 Apr; 20(4):343-8. PubMed ID: 16161186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing the bioavailability of itraconazole.
    Grant EM
    Conn Med; 2000 Jul; 64(7):415-7. PubMed ID: 10946480
    [No Abstract]   [Full Text] [Related]  

  • 20. Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient.
    Main KM; Skov M; Sillesen IB; Dige-Petersen H; Müller J; Koch C; Lanng S
    Acta Paediatr; 2002; 91(9):1008-11. PubMed ID: 12412882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.